{"analyses":[{"ciLowerLimit":"0.29","ciNumSides":"TWO_SIDED","ciPctValue":"95","ciUpperLimit":"0.56","groupIds":["OG000","OG001"],"nonInferiorityType":"SUPERIORITY","pValue":"0.00000001","paramType":"Hazard Ratio (HR)","paramValue":"0.41","statisticalComment":"Stratified","statisticalMethod":"Log Rank"}],"classes":[{"categories":[{"measurements":[{"comment":"NA: not able to calculate the upper bounds of the 95% Confidence Interval due to insufficient number of participants with events","groupId":"OG000","lowerLimit":"6.77","upperLimit":"NA","value":"9.30"},{"groupId":"OG001","lowerLimit":"4.04","upperLimit":"5.95","value":"5.55"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"233"},{"groupId":"OG001","value":"234"}],"units":"Participants"}],"description":"rPFS is defined as the time to radiographic progression by Prostate cancer working Group 3 (PCWG3)-modified RECIST v1.1 as assessed by Blinded independent central (BICR) review or death.","dispersionType":"95% Confidence Interval","groups":[{"description":"Participants received 7.4 GBq (200 mCi) +/- 10% 177Lu-PSMA-617 once every 6 weeks for 6 cycles. Best supportive care, including ADT could be used.","id":"OG000","title":"177Lu-PSMA-617 (AAA617)"},{"description":"For participants randomized to the ARDT arm, the change of ARDT treatment was administered per the physician's orders. Best supportive care, including ADT could be used.","id":"OG001","title":"Androgen Receptor-directed Therapy (ARDT)"}],"paramType":"MEDIAN","populationDescription":"The Full Analysis Set (FAS) comprised all participants to whom study treatment was assigned by randomization.","reportingStatus":"POSTED","timeFrame":"median FU (randomization to event or censoring) 3.65 months (range 0-12.3)","title":"Radiographic Progression Free Survival (rPFS)","type":"PRIMARY","unitOfMeasure":"months"}